Skip to main content

Market Overview

Aptinyx Stock Is Trading Higher After Restarting NYX-458 Study In Dementia Associated Cognitive Impairment

Share:
Aptinyx Stock Is Trading Higher After Restarting NYX-458 Study In Dementia Associated Cognitive Impairment
  • Aptinyx Inc (NASDAQ: APTX) has restarted patient screening in a Phase 2 study evaluating NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinson's disease and dementia with Lewy bodies.
  • Aptinyx will release the data from this study in the second half of 2022.
  • The screening was halted due to COVID-19 related restrictions.
  • The Phase 2 study is a randomized, double-blind, parallel-design, placebo-controlled study conducted in approximately 100 patients.
  • The study will evaluate the overall safety and tolerability of NYX-458 30 mg daily oral dosing compared to placebo over 12 weeks. 
  • NYX-458 is a novel oral NMDA receptor modulator.
  • Price Action: APTX shares jump 9.01% higher at $3.51 in the premarket trading on the last check Tuesday.
 

Related Articles (APTX)

View Comments and Join the Discussion!

Posted-In: Briefs dementiaBiotech News Penny Stocks Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com